VIDEO: Consensus conference seeks ‘standardization’ of care in pregnant women with IBD
Click Here to Manage Email Alerts
In this video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, spoke with Healio about a consensus conference on the management of IBD in pregnancy.
The session, held during Digestive Disease Week 2024, included presentations from medical experts and patient advocates.
Mahadevan explained that the panel found that women with IBD should be in remission going into pregnancy, as “disease activity is the biggest driver for adverse outcomes for the mother and the baby.
“In order to do that, women can and should continue their monoclonal antibody therapy throughout conception and pregnancy,” she said.
Mahadevan noted that the treatments patients with IBD should continue throughout pregnancy include anti-TNF therapies, ustekinumab (Stelara, Janssen), vedolizumab (Entyvio, Takeda Pharmaceuticals) and IL-23s, and that it is recommended to stop treatment with Sphingosine-1-phosphate receptor modulators and JAK inhibitors prior to conception unless there are no other viable treatments for the patient.
The session included recommendations on rotavirus vaccination in infants born to women with IBD, classifying pregnancies in women with IBD as high-risk and therapeutics during lactation.
“We hope that this global consensus will bring standardization and improvement of care for women with IBD around the globe,” Mahadevan said.
Reference:
- Mahadevan U, et al. Dr. Ellen Scherl-Jill Roberts Lecture - Pregnancy and IBD: Preliminary Results from the Helmsley Global Consensus Grade Conference. Presented at: Digestive Disease Week; May 18-21, 2024; Washington (hybrid).
Collapse
Healio Interviews
Click Here to Manage Email Alerts